Modeling Fanconi anemia pathogenesis and therapeutics using integration-free patient iPSCs

Fanconi anaemia (FA) is a recessive disorder characterized by genomic instability, congenital abnormalities, cancer predisposition and bone marrow (BM) failure. However, the pathogenesis of FA is not fully understood partly due to the limitations of current disease models. Here, we derive integratio...

ver descrição completa

Detalhes bibliográficos
Autores: Liu, Guang-Hui, Suzuki, Keiichiro, Li, Mo, Qu, Jing, Montserrat, Núria, Tarantino, Carolina|||0000-0003-2470-3803, Gu, Ying, Yi, Fei, Xu, Xiuling, Zhang, Weiqi|||0000-0002-2535-1398, Ruiz, Sergio, Plongthongkum, Nongluk, Zhang, Kun, Masuda, Shigeo, Nivet, Emmanuel, Tsunokawa, Yuji, Soligalla, Rupa Devi, Goebl, April, Aizawa, Emi, Kim, Na Young, Kim, Jessica, Dubova, Ilir, Li, Ying|||0000-0002-5377-6262, Ren, Ruotong, Benner, Chris, Sol, Antonio del, Bueren, Juan|||0000-0002-3228-7013, Trujillo Quintero, Juan Pablo, Surralles, Jordi|||0000-0002-4041-7519, Cappelli, Enrico, Dufour, Carlo, Rodriguez Esteban, Concepción, Izpisúa Belmonte, Juan Carlos
Formato: artículo
Fecha de publicación:2014
País:España
Recursos:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:132523
Acesso em linha:https://ddd.uab.cat/record/132523
https://dx.doi.org/urn:doi:10.1038/ncomms5330
Access Level:acceso abierto
Palavra-chave:Fanconi anemia
Descrição
Resumo:Fanconi anaemia (FA) is a recessive disorder characterized by genomic instability, congenital abnormalities, cancer predisposition and bone marrow (BM) failure. However, the pathogenesis of FA is not fully understood partly due to the limitations of current disease models. Here, we derive integration free-induced pluripotent stem cells (iPSCs) from an FA patient without genetic complementation and report in situ gene correction in FA-iPSCs as well as the generation of isogenic FANCA-deficient human embryonic stem cell (ESC) lines. FA cellular phenotypes are recapitulated in iPSCs/ESCs and their adult stem/progenitor cell derivatives. By using isogenic pathogenic mutation-free controls as well as cellular and genomic tools, our model serves to facilitate the discovery of novel disease features. We validate our model as a drug-screening platform by identifying several compounds that improve hematopoietic differentiation of FA-iPSCs. These compounds are also able to rescue the hematopoietic phenotype of FA patient BM cells.

Registos relacionados